Simoa® technology enables breakthrough research.

In late 2021, Quanterix announced that its Simoa® phospho-Tau 181 (pTau181) blood test was granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s Disease (AD). A distinction not shared by any other company.

This designation is a major milestone for AD research and underscores the potential of the Simoa technology to revolutionize AD research and help bring much needed clarity to what has been a very complex and difficult disease to diagnose.

The need for a more sensitive method of measuring pTau181, a critical biomarker associated with Alzheimer’s Disease (AD), is becoming increasingly important as we continue to see a rise in this disease worldwide. Researchers globally have demonstrated that the Simoa pTau181 assay by Quanterix plays a pivotal role in the pursuit of breakthroughs in early detection and prevention of AD.

QUANTERIX OFFERS THE FOLLOWING OPTIONS BASED ON YOUR RESEARCH NEEDS.

- Purchase assay Simoa 181 assay kits, available on either the HD-X or SR-X testing platforms
- Submit samples to our Accelerator Laboratory for analysis
- Partner with us to customize your own pTau181 assay that suit your research goals

Visit quanterix.com for more information.
Simoa pTau181 assay has powered more than 60 peer-reviewed publications on the alone in 2022.